Literature DB >> 6106364

Difference of effective antitrypanosomal dosages of benznidazole in mice and man. Chemotherapeutic and pharmacokinetic results.

R W Richle, J Raaflaub.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6106364

Source DB:  PubMed          Journal:  Acta Trop        ISSN： 0001-706X            Impact factor:   3.112


× No keyword cloud information.
  13 in total

1.  Trypanocidal drugs and their effect on parasitaemia, specific IgG production and protective immunity in rats infected with Trypanosoma lewisi.

Authors:  C M Ndarathi
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

2.  Vismione B Interferes with Trypanosoma cruzi Infection of Vero Cells and Human Stem Cell-Derived Cardiomyocytes.

Authors:  Gabriele Sass; Armelle T Tsamo; Gwladys A M Chounda; Pamela K Nangmo; Nazish Sayed; Adriana Bozzi; Joseph C Wu; Augustin E Nkengfack; David A Stevens
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

3.  Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole.

Authors:  María Elena Marson; Jaime Altcheh; Guillermo Moscatelli; Samanta Moroni; Facundo García-Bournissen; Guido Enrique Mastrantonio
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-04-08       Impact factor: 2.441

4.  Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease.

Authors:  Matthew O Wiens; Steve Kanters; Edward Mills; Alejandro A Peregrina Lucano; Silvia Gold; Dieter Ayers; Luis Ferrero; Alejandro Krolewiecki
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

5.  Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical Trials.

Authors:  I Molina; F Salvador; A Sánchez-Montalvá; M A Artaza; R Moreno; L Perin; A Esquisabel; L Pinto; J L Pedraz
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

7.  The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice.

Authors:  F W Jennings; G M Urquhart
Journal:  Z Parasitenkd       Date:  1983

8.  The use of 2-substituted 5-nitroimidazoles in the treatment of chronic murine Trypanosoma brucei infections with central nervous system involvement.

Authors:  F W Jennings; G M Urquhart; P K Murray; B M Miller
Journal:  Z Parasitenkd       Date:  1984

9.  Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.

Authors:  Shilpi Khare; Xianzhong Liu; Monique Stinson; Ianne Rivera; Todd Groessl; Tove Tuntland; Vince Yeh; Ben Wen; Valentina Molteni; Richard Glynne; Frantisek Supek
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

Review 10.  Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.

Authors:  Facundo Garcia-Bournissen; Jaime Altcheh; Norberto Giglio; Guido Mastrantonio; Carlos Omar Della Védova; Gideon Koren
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.